

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

		** *		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/610,891	07/06/2000	James McArthur	40567	6712
7590 01/30/2006		EXAMINER		
Steven B Kelber Esq			YU, MISOOK	
			ART UNIT	PAPER NUMBER
			1642	
			DATE MAILED: 01/30/2006	6
	09/610,891 759 Steven B Kelb Piper Rudnick L 1200 19th Street	09/610,891 07/06/2000 7590 01/30/2006	09/610,891 07/06/2000 James McArthur 7590 01/30/2006 Steven B Kelber Esq Piper Rudnick LLP 1200 19th Street N W	09/610,891 07/06/2000 James McArthur 40567 7590 01/30/2006 EXAM Steven B Kelber Esq YU, MI Piper Rudnick LLP ART UNIT 1200 19th Street N W ART UNIT Washington, DC 20036 1642

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	09/610,891	MCARTHUR ET AL.	
Office Action Summary	Examiner	Art Unit	
	MISOOK YU, Ph.D.	1642	
The MAILING DATE of this communicati	on appears on the cover sheet wi	th the correspondence address	
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR WHICHEVER IS LONGER, FROM THE MAIL! - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communica - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, b Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF THIS COMMUNIC CFR 1.136(a). In no event, however, may a re- tion. period will apply and will expire SIX (6) MON' y statute, cause the application to become AB	CATION. Exply be timely filed IHS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).	
Status			
1)⊠ Responsive to communication(s) filed or	25 February 2005 and 11 July :	2005	
	This action is non-final.	<u>:000</u> .	
3) Since this application is in condition for a		ers, prosecution as to the merits is	
closed in accordance with the practice u	·	·	
·	pano Quayio, 1000 0.2	. 11, 100 0.0.210.	
Disposition of Claims			
4)⊠ Claim(s) <u>35-40 and 44-52</u> is/are pending	• •		
4a) Of the above claim(s) <u>48-52</u> is/are wi	thdrawn from consideration.		
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>35,37,38 and 40</u> is/are rejected			
7) Claim(s) <u>36,39 and 44-47</u> is/are objected			
8) Claim(s) are subject to restriction	and/or election requirement.		
Application Papers			
9) The specification is objected to by the Ex	aminer.		
10) The drawing(s) filed on is/are: a)	☐ accepted or b)☐ objected to t	by the Examiner.	
Applicant may not request that any objection	to the drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the	correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).	
11) The oath or declaration is objected to by	the Examiner. Note the attached	Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of:	oreign priority under 35 U.S.C. §	119(a)-(d) or (f).	
1. Certified copies of the priority doct	uments have been received.		
2. Certified copies of the priority doct		oplication No.	
3. Copies of the certified copies of th		· ·	
application from the International E	-		
* See the attached detailed Office action for		received.	
Attachment(s)			
1) Notice of References Cited (PTO-892)		ummary (PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-9)/Mail Date formal Patent Application (PTO-152)	
Information Disclosure Statement(s) (PTO-1449 or PTO/ Paper No(s)/Mail Date	SB/08) 5) Notice of In		

Application/Control Number: 09/610,891 Page 2

Art Unit: 1642

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 25 February 2005 and 11 July 2005 has been entered.

Claims 48-59 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) from the examination for reason of record. Claims 35-40 and 44-52 are pending. Claims 35-40 and 44-47 are examined on merits.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

This Office action contains new grounds of rejections.

Specification, Maintained

The specification remains objected because the trademark GVAX is not be accompanied by the generic terminology. It is not clear what the single bracket surrounding GVAX means in the amendment to the specification filed on 15 July 2005 Adding the generic terminology for the trademark GVAX at its first occurrence would obviate this objection.

Application/Control Number: 09/610,891

Art Unit: 1642

Claim Rejections - 35 USC § 103, Withdrawn

The rejection of claims 35-39 and 44-47 under 35 U.S.C. 103(a) as being unpatentable over Sanda et al., J Urol. 1994 Mar;151(3):622-8, in view of Savarese et al., Prostate. 1998 Feb 1;34(2):80-91, and further in view of Thomas et al., Hum Gene Ther. 1998 Apr 10;9(6):835-43 is withdrawn because of applicant's persuasive arguments.

Claim Rejections - 35 USC § 102

Claims 35, 37, 38 and 40 rejected under 35 U.S.C. 102(b) as being anticipated by Wollin et al., Radiother Oncol. 1989 Jul;15(3):285-93, abstract only with this Office action. The full journal would be provided when available.

Claims 35, 37, 38 and 40 are drawn to a composition comprising a GM-CSF-expressing proliferation-incompetent PC3, or DU145.

Wollin et al., teach a composition comprising irradiated PC3, or DU145.

According to either Lang et al., International Journal of Cancer 59 (2): p235-241 1994 abstract only, or Rockhlin et al., Anticancer Research (ANTICANCER RES.) (Greece) 1996, 16/2 (557-563 abstract only, both PC3, or DU145 expresses GM-CSF. As for the limitation "proliferation-incompetent", the specification at page 9 lines 12-15 discloses "proliferation- incompetent" refers to cells which are unable to divide, but which express genes encoding tumor associated proteins, and the instant specification at page 64, line 28 for example, discloses "irradiated" prostate cell lines before administration. Thus, the instant specification as a whole teaches that irradiation makes tumor cells "proliferation-incompetent". As for in vivo immune responses with the various molecular

Application/Control Number: 09/610,891 Page 4

Art Unit: 1642

weights, the instant claim 35 says that a composition comprising irradiated PC3, or DU145 has the ability to produce such response.

Conclusion

The objected claims are objected because they depend on the rejected base claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner
Art Unit 1642